Genetic Variations of OPRM1, OPRK1, and COMT Genes and Their Possible Associations with Oral Pain in a Population from Argentina

Aims: To analyze in a population from Argentina the variation of three genes involved in the control of pain pathways—two genes that code for opioid receptors (OPRM1 and OPRK1) and COMT, which codes for an important enzyme in the control of neurotransmission—and to evaluate the associations of these genes with oral pain and the need for analgesics in the population under study. Methods: A total of 134 volunteer donors from the city of Resistencia and 27 donors from the Wichí community for comparison were analyzed for 13 single nucelotide polymorphisms (SNPs) and 1 insertion/deletion (Indel) localized in the three genes using polymerase chain reaction-restriction fragment length polymorphism or standard PCR and electrophoresis. All 134 individuals from Resistencia provided biologic samples for DNA analysis, and a subset (n = 81) agreed to answer a questionnaire for an association analysis. Statistical tests for a possible association between genetic variation and self-reported ethnic origin, oral pain, and need for analgesic drugs were performed. Results: Significant differences were found when the study population was compared to populations from other continents, as well as between the two studied populations (P < .05). A positive association was suggested for the COMT gene from Resistencia with both oral pain intensity and analgesic requirements. Conclusion: The admixture process that occurred in the past of Resistencia probably contributed to a genetic differentiation in this population, and this genetic variation might influence phenotypic expressions of pain perception and analgesic requirements.

admixed population;pain genetics;pain perception;single nucleotide polymorphisms

1.Mogil JS. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci 1999 U S A 1999;96:7744–7751.

2.Lacroix-Fralish ML, Mogil JS. Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol 2009;49:97–121.

3.Fillingim RB, Wallace MR, Herbstman DM, Ribeiro-Dasilva M, Staud R. Genetic contributions to pain: A review of findings in humans. Oral Dis 2008;14:673–682.

4.Foulkes T, Wood JN. Pain genes. PLoS Genet 2008;4: e1000086.

5.Menon S, Lea RA, Roy B, et al. The human µ-opioid receptor gene polymorphism (A118G) is associated with head pain se-verity in a clinical cohort of female migraine with aura patients. J Headache Pain 2012;13:513–519.

6.Desmeules JA, Piguet V, Ehret GB, Dayer P. Pharmacogenetics, pharmacokinetics and analgesia. In: Mogil JS (ed). The Genetics of Pain. Seattle: IASP, 2004:211–238.

7.Yu L. Pharmacogenetics: The OPRM (mu-opioid-receptor) gene. In: Mogil JS (ed). The Genetics of Pain. Seattle: IASP, 2004:239–256.

8.Mayer P, Höllt V. Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther 2001;91:167–177.

9.Bond C, LaForge KS, Tian M, et al. Single-nucleotide poly-morphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998;95:9608–9613.

10.Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the hu-man mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001;276:3130–3137.

11.Klepstad P, Rakvåg TT, Kaasa S, et al. The 118 A > G poly-morphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malig-nant disease. Acta Anaesthesiol Scand 2004;48:1232–1239.

12.Yuferov V, Fussell D, LaForge KS, et al. Redefinition of the hu-man kappa opioid receptor gene (OPRK1) structure and asso-ciation of haplotypes with opiate addiction. Pharmacogenetics 2004;14:793–804.

13.Xuei X, Dick D, Flury-Wetherill L, et al. Association of the kap-pa-opioid system with alcohol dependence. Mol Psychiatry 2006;11:1016–1024.

14.Edenberg HJ, Wang J, Tian H, et al. A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. Hum Mol Genet 2008;17:1783–1789.

15.Kumar D, Chakraborty J, Das S. Epistatic effects between vari-ants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:225–230.

16.Zhang W, Chang YZ, Kan QC, et al. Association of human mi-cro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 2010;65:130–135.

17.Levran O, Yuferov V, Kreek MJ. The genetics of the opioid system and specific drug addictions. Hum Genet 2012;131:823–842.

18.López Soto EJ, Catanesi CI. Human population genetic struc-ture detected by pain-related mu opioid receptor gene poly-morphisms. Genet Mol Biol 2015;38:152–155.

19.Loh el W, Fann CS, Chang YT, Chang CJ, Cheng AT. Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. Alcohol Clin Exp Res 2004;28:15–19.

20.Huerta D, Acosta O, Polo S, Martínez R, Oré R, Miranda C. Polimorfismo Val108/158Met en el gen dopaminérgico cate-col-o-metil transferasa (COMT) en una población mixta pe-ruana y su importancia para los estudios neuropsiquiátricos. Anales de la Facultad de Medicina 2007;68:321–327.

21.Vargas-Alarcón G, Fragoso JM, Cruz-Robles D, et al. Catechol-O- methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 2007;9:R110.

22.Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008;4:64.

23.Ross JR, Riley J, Taegetmeyer AB, et al. Genetic variation and response to morphine in cancer patients: Catechol-O-methyltransferase and multidrug resistance-1 gene polymor-phisms are associated with central side effects. Cancer 2008; 112:1390–1403.

24.Henker RA, Lewis A, Dai F, et al. The association between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol Res Nurs 2013;15:309–317.

25.Kim H, Mittal DP, Iadarola MJ, Dionne RA. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J Med Genet 2006;43:e40.

26.Mladenovic I, Supic G, Kozomara R, et al. Genetic polymor-phisms of catechol-O-methyltransferase: Association with temporomandibular disorders and postoperative pain. J Oral Facial Pain Headache 2016;30:302-310.

27.Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variation of pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14:135–143.

28.Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006;125:216–224.

29.Vargas-Alarcón G, Alvarez-Leon E, Fragoso JM, et al. A SCN9A gene-encoded dorsal root ganglia sodium chan-nel polymorphism associated with severe fibromyalgia. BMC Musculoskelet Disord 2012;13:23.

30.Tammimäki A, Männistö PT. Catechol-O-methyltransferase gene polymorphism and chronic human pain: A systematic re-view and meta-analysis. Pharmacogenet Genomics 2012;22: 673–691.

31.Maeder EJA. Historia del Chaco. Buenos Aires: Editorial ConTexto, 2012.

32.de Pompert de Valenzuela MC. El poblamiento del Chaco: Génesis y primitivo desarrollo. Correntes, Argentina: 2008.

33.Avena S, Via M, Ziv E, Pérez-Stable EJ, et al. Heterogeneity in genetic admixture across different regions of Argentina. PLoS One 2012;7:e34695.

34.Sevini F, Yao DY, Lomartire L, et al. Analysis of population substructure in two sympatric populations of Gran Chaco, Argentina. PLoS One 2013;8:e64054.

35.Mendez MG. Niños y Madres. Estudios antropológicos sobre reproducción y fertilidad. La Plata, Argentina: 2013.

36.Tang H. Confronting ethnicity-specific disease risk. Nat Genet 2006;38:13–15.

37.Censo Nacional de Población, Hogares y Viviendas 2010. Censo del Bicentenario Pueblos Originarios Región Nordeste Argentino. http://trabajo.gob.ar/downloads/pueblosindigenas/pueblos_originarios_NEA.pdf. Accessed 9 August 2018.

38.Gemmell NJ, Akiyama S. An efficient method for the ex-traction of DNA from vertebrate tissues. Trends Genet 1996; 12:338–339.

39.Fink R. Pain assessment: The cornerstone to optimal pain management. Proc (Bayl Univ Med Cent) 2000;13:236–239.

40.Brevik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth 2008;101:17–24.

41.Gelernter J, Kranzler HR, Cubells J. Genetics of two mu opi-oid receptor gene (OPRM1) exon I polymorphisms: Population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 1999;4:476–483.

42.Bergen AW, Kokoszka J, Peterson R, et al. Mu opioid receptor gene variants: Lack of association with alcohol dependence. Mol Psychiatry 1997;2:490–494.

43.Smith RJ, Doyle GA, Han AM, et al. Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. Am J Med Genet B Neuropsychiatr Genet 2005;133B:105–109.

44.Beuten J, Payne TJ, Ma JZ, Li MD. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nic-otine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 2006;31:675–684.

45.Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): An in-tegrated software package for population genetics data analy-sis. Evol Bioinform Online 2007;1:47–50.

46.1000 Genomes Browser. https://www.ncbi.nlm.nih.gov/varia-tion/tools/1000genomes/. Accessed 9 August 2018.

47.Skarke C, Kirchhof A, Geisslinger G, Lötsch J. Comprehensive mu-opioid-receptor genotyping by pyrosequencing. Clin Chem 2004;50:640–644.

48.Devoto F. La inmigración de ultramar. In: Torrado S (ed). Población y Bienestar en la Argentina del Primero al Segundo Centenario: Una Historia Social del Siglo XX. Buenos Aires: Edhasa, 2007:531–548.

49.Salas A, Jaime JC, Álvarez-Iglesias V, Carracedo Á. Gender bias in the multiethnic genetic composition of central Argentina. J Hum Genet 2008;53:662–674.

50.Avena SA, Goicoechea A, Rey J, Dugoujon J, Dejean C, Carnese FR. Gene mixture in a population sample from Buenos Aires City [in Spanish]. Medicina (B Aires) 2006;66:113–118.

51.Parolín ML, Carnese FR. HLA-DRB1 alleles in four Amerindian populations from Argentina and Paraguay. Genet Mol Biol 2009;32:212–219.

52.Demarchi DA. Análisis de la estructura genética en pobla-ciones nativas del Gran Chaco. Folia Histórica del Nordeste 2014;22:169–185.

53.Crossetti SG, Demarchi DA, Raimann PE, Salzano FM, Hutz MH, Callegari-Jacques SM. Autosomal STR genetic variability in the Gran Chaco Native Population: Homogeneity or hetero-geneity? Am J Hum Biol 2008;20:704–711.

54.Franceschi ZA, Dasso MC. Etno-grafías: La escritura como testimonio entre los wichí. Buenos Aires: Corregidor, 2010.

55.Glesmann LA, Martina PF, Catanesi CI. Genetic variation of X-STRs in the Wichí population from Chaco province, Argentina. Hum Biol 2013;85:687–698.

56.Catanesi CI, Glesmann LA. Genetic drift among native people from South American Gran Chaco region affects interleukin 1 receptor antagonist variation. In: Richardson J (ed). Natural Selection and Genetic Drift. New York: Nova Science, 2016.

57.Ittiwut R, Listman JB, Ittiwut C, et al. Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet 2011;156B:651-660.

58.Seldin MF, Tian C, Shigeta R, et al. Argentine population ge-netic structure: Large variance in Amerindian contribution. Am J Phys Anthropol 2007;132:455–462.